Thirty-four years after its original recording, Candid Records has released a jazz CD to honor the memory of noted British journalist and musician Keith Shadwick, with all proceeds from the sale going to Bart’s Mesothelioma Research, a charity based in the UK dedicated to studying the asbestos related disease.

Shadwick, who passed away from mesothelioma on July 28, 2008, was a respected journalist and author whose background as a jazz and rock musician in the 1970s led to a career focus on music and musicians. His credits include books on noted jazz musician Bill Evans, as well as Jimi Hendrix and Led Zeppelin. He also authored The Jazz & Blues Encyclopedia, the Guinness Guide to Classical Composers, and edited The Gramophone Good CD Guide. Additionally, he was a regular contributor to publications including Jazzwise magazine, The Independent and The Daily Mail.

According to an article published on All About Jazz.com, during his early 20s, Shadwick was a jazz and jazz/rock musician, playing saxophone, flute and piano. He was a founding member of the Sydney, Australia-based group, Sun, which released one self-titled album in 1972 before splitting up. In 1973 and 1974, the story reports, Shadwick and fellow Sun member, drummer Gary Norwell, recorded some jazz tracks with fellow musicians Justin McCoy and Robert Luckey when local Point Five Studio offered them use of its facility during a free downtime.

As a nod to their luck in securing the studio, the musicians named the album Free Time, but it was not completed or released. Shadwick held onto the tapes, and revived work on the recording in 1984, with guitarist Billy Jenkins, and again in 2005, with guitarist Mike Wollenberg.

All About Jazz notes that Shadwick was motivated to finish the album in 2005, when he was diagnosed with mesothelioma, and completed the project in 2007, although it is unlikely that he lived long enough to see its official pressing, which was delivered to his home right around the time of his death. The album was produced and released by Candid Records in the UK.

The Special Edition of the Free Time CD is available in limited release through the Candid Records web site, with all proceeds benefitting Bart’s Mesothelioma Research. Cost is £9.99 plus shipping, which totals around $24 U.S.

The Environmental Protection Agency (EPA) Science Advisory Board (SAB) Asbestos Committee held public meetings July 21 and 22 in Washington, D.C., to discuss changes in the way it measures the risk posed by inhalation exposure to asbestos. Results of this meeting are coming under fire, as environmental groups, labor safety leaders, physicians, scientists and politicians object to the EPA’s proposed revised evaluation standards.

According to recent report in the Seattle Post-Intelligencer, there were 20 experts appointed to the SAB’s asbestos panel, charged with evaluating the validity of the EPA’s plan to change how the toxicity of the six types of asbestos regulated by the government differ in danger. Its findings would be submitted to the White House Office of Management and Budget (OMB).

According to the PI report, scientific advisors say the EPA used the asbestos panel to submit new studies that contradict longstanding research into the dangers of asbestos. The new studies say chrysolite, in particular, the most common type of asbestos, isn’t dangerous and doesn’t cause mesothelioma.

PI quotes Dr. David Egilman, an occupational medicine specialist, who testified at the public meeting, as saying the new study was financed by mining and other asbestos-related industries, and said the studies have no scientific credibility.

Another vocal spokesperson at the hearing was Sen. Patty Murray, who sponsored S. 742, the Ban Asbestos in America Act of 2007, which passed the Senate on Oct. 4, 2007. Currently, it is the companion bill to H.R. 3339, the Bruce Vento Ban Asbestos and Prevent Mesothelioma Act, sponsored by Rep. Betty McCollum, which currently is in committee in the House of Representatives.

Sen. Murray has long been an advocate for a total asbestos ban, calling for better worker protection. The PI quotes Sen. Murray as telling the committee, “I’d like the political appointees at the EPA to look into the eyes of a mesothelioma patient and say that asbestos isn’t dangerous. It appears that this administration is once again putting politics before public health.” Murray is currently chairwoman of the Senate Employment and Workplace Safety Subcommittee.

The EPA asserts the new system is needed to improve how asbestos-contaminated Superfund sites are evaluated. The organization can move forward with its proposal without approval from the OMB or the SAB, if it so chooses.

The Centers for Disease Control (CDC) recently announced a new program to provide $30 million in grant money for health screenings, assessments, monitoring and tracking, and improved access to health care services and treatments for those who may have been impacted by the World Trade Center collapse on Sept. 11. The grant will be available not only to first responders and other workers, but also to hundreds of thousands of Manhattan residents who live or lived near the Twin Towers.

The buildings’ collapse released thousands of pounds of hazardous material into the atmosphere, which may have included a combination of glass, asbestos, fiberglass, pulverized concrete, lead, mercury, cadmium, dioxins and PCBs. Construction of the World Trade Center buildings was begun before the use of asbestos was banned in the U.S., and some estimates say as much as 400 tons of asbestos fiber was in the buildings.

People near Ground Zero could experience a number of medical problems as a result of their exposure to this toxic dust, including respiratory problems and asbestos disease including mesothelioma.

In an official release from the CDC, Christine Branche, acting director of the CDC’s National Institute for Occupational Safety and Health (NIOSH), said, “These public health dollars extend the reach of our efforts so that they help support the provision of the health care services to residents, students, an others who were in the vicinity of the attacks of September 11, 2001.”

The release says the NIOSH-administered grants provide up to $10 million per year for three years, and the money can be used to help cover gaps when individuals’ public or private insurance is insufficient to fully cover the costs associated with care or treatment.

Funding will be provided to one to three organizations, with the deadline for proposal submission set for Aug. 25, 2008. For more information about how to apply for one of these grants, visit www.Grants.gov. The CDC encourages health and medical care facilities to apply.

The CDC says it already has invested at least $925 million in programs to support responders to the 9/11 emergency.

In the first days of writing this blog, I linked to a very inspirational video by Dr. Randy Pausch, popularly called The Last Lecture. Pausch, a 47-year-old Professor of Computer Science, Human-Computer Interaction, and Design at Carnegie Mellon University (CMU) in Pittsburgh, Pennsylvania had been diagnosed with terminal pancreatic cancer, and created the lecture to inspire others to make the most of the time they have here on earth.

Based on the idea of “living your childhood dreams,” the lecture is a reflection on what would be most important to a person if they had to choose the last talk of their life – the things they would want to share with others.

Dr. Pausch passed away today, at the age of 47. He is survived by his wife, Jai, and their three children, Dylan, Logan and Chloe; his mother, Virginia Pausch of Columbia, Md.; and a sister, Tamara Mason of Lynchburg, Va.

Please take the time to watch this video. I hope that it inspires you to live your dreams.

Researchers in Denmark have discovered a chemotherapy combination that is proving to be highly effective for people with non-resectable malignant mesothelioma, according to a recent report on CancerConsultants.com. The study was published in a June issue of the British Journal of Cancer.

According to the report, the study evaluated a regimen of Navelbine (vinorelbine) and Platinol (cisplatin) for the treatment of 54 patients with newly diagnosed non-resectable mesothelioma. The median number of cycles of chemotherapy administered was four. There were two complete responses and 14 partial responses.

The median survival was 16.8 months, and the median time to tumor progression was 7.2 months. The one-year survival was 61 percent, the two-year survival was 31 percent, and the three-year survival was 4 percent.

The authors of the study say these results are as good as or better than currently used combinations for treatment of mesothelioma.

This is a reminder to those who haven’t yet contacted their representative in U.S. Congress about H.R. 3339, the Bruce Vento Ban Asbestos and Prevent Mesothelioma Act. Please take the time to do this right now! It’s very important to let your Representative on Capitol Hill know that you support this measure to finally ban asbestos in the U.S. and provide funding for mesothelioma research.

The bill is currently in committee, with the House Committee on Energy and Commerce. Even if your district’s representative is not on this committee, it is important to let him or her know that you support the bill so that they know how to vote. The more voices they hear from their constituency, the better chance they will pay attention when this finally comes to the House floor.

If your representative IS a member of this committee, it is even more important. Many bills “die” in committee, never making it to a vote of the full House or Senate. Please make sure your representative helps get this bill approved in committee and to the floor for its vote.

My representative, Terry Everett (2nd District, Alabama), acknowledged his receipt of my request with a letter, in which he said he will keep my thoughts in mind should the bill make it to the floor, although he is not a member of the Committee on Energy and Commerce.

According to information provided by Everett’s office, H.R. 3339 would require several actions to be taken by the federal government in addressing asbestos and its harmful effects. The Environmental Protection Agency (EPA) would establish a plan to increase awareness of the dangers posed by asbestos-containing materials in homes and workplaces and encourage participation in research and treatment endeavors of asbestos-related disease patients.

The bill also would require the disposal of asbestos-containing materials within two years and the prohibition on the importing, manufacturing, processing or distributing of asbestos-containing materials, except for specific exemptions sought by the Department of Defense and National Aeronautics and Space Administration.

If you are not sure of the representative for your Congressional District, visit the House of Representatives online. You can also find out here if your representative is a member of the House Committee on Energy and Commerce.

Please take the time to do this today. Your one voice is SO important. Let it join thousands of others to finally make a real difference.

Today Alfacell, the manufacturer of ONCONASE, announced it will begin distribution of the mesothelioma drug in Israel. The company will partner with Megapharm, Ltd., a leading pharmaceutical company in Israel. ONCONASE recently completed an international confirmatory Phase IIIb clinical trial for unresectable malignant mesothelioma.

The news comes just a day after Haaretz.com, a leading news outlet in Israel, noted that asbestos-related cancer is 10 times more prevalent in Nahariya, a city of approximately 50,000 located in the North District of Israel on the Mediterranean sea, just south of the Lebanese border at Rosh HaNikra, than it is in the rest of the country. The report is based on data submitted by the chief doctor of the Health Ministry’s Acre District.

The medical report was presented to the Knesset Internal Affairs Committee, which is currently calling for greater action from Nahariya’s government to address the problem. The story quotes Tamar Bar On, head of the Environment Ministry’s Asbestos Department, as saying that “between 70 to 150 thousand cubic meters of asbestos [can] be found scattered across the Western Galilee, mainly in private yards.”

Committee MK Yossi Beilin (Meretz) has been selected by the committee to chair a panel dedicated to addressing the asbestos problem in Nahariya.

Alfacell will manufacture and supply ONCONASE to Megapharm, while Megapharm will be responsible for all activities and costs related to regulatory filings and commercial activities in a defined marketing territory, according to an Alfacell press release.

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell’s proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

Today I came across a blog that explores alternative treatments for cancer, of all types. Our friend Charlene Kaforey, who recently experienced good results for her mesothelioma with an alternative cancer vaccine program at the ITL Alternative Cancer Treatment Clinic in the Bahamas, posted her story to the site. The blog is a project of Jonathan Chamberlain, who authored two books about alternative therapies after losing his wife, Bernadette, to cervical cancer in 1994.

The blog, called the Cancerfighter’s Weblog, explores “alternative cancer therapies and ideas,” touching on a wide range of topics that also includes general health and wellness through alternative, holistic or natural medicines and practices. He encourages people like Charlene, who are trying non-traditional therapies, to share their stories and experiences with others, and provides a forum for people to ask questions.

John has another web site, Fighting Cancer: A Survival Guide, where he shares some personal stories of his and Bernadette’s life, and addresses topics including how to deal with a diagnosis of cancer, advice for caregivers, stories of good and bad experiences with alternative treatments, and good and bad stories about orthodox treatments.

An English teacher living in Hong Kong, John has authored textbooks for secondary school students, and also has written a number of other books on topics including Chinese folk religion, a profile of a famous Chinese gambler, and a touching biography about the life of his daughter, Stevie, who had Down Syndrome.

A couple days ago I talked about the NPR blogger Leroy Sievers, who writes “My Cancer” about his experiences since being diagnosed with a brain tumor two years ago. Sievers will be featured on the NPR program Talk of the Nation tomorrow, July 9, along with Elizabeth Edwards, wife of former presidential candidate and Senator John Edwards, for a special show about living with cancer. The special program will be hosted by Ted Koppel, and you can participate!

Elizabeth Edwards is a breast cancer survivor who currently is battling a recurrence of her cancer, as a small tumor in her bone.

Sievers worked with Koppel for 14 years on the news program Nightline before joining NPR, and their conversations about Sievers’ experience were the core of Koppel’s three-hour primetime Discovery Channel special Living with Cancer that aired in 2007.

Talk of the Nation airs midday. For local stations and broadcast times in your area, visit www.NPR.org/stations.

Listeners can participate in this program by calling 1-800-989-8255 or emailing talk@npr.org. The program also is available as streaming audio and as a daily podcast at www.NPR.org and on the “NPR Now” and “NPR Talk” 24/7 public radio channels on Sirius satellite radio.

A New York medical center specializing in the treatment of mesothelioma has announced a new clinical trial accepting patients. The Mesothelioma Center within the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center is launching a program of targeted radiation and chemotherapy protocol for pleural mesothelioma, a cancer of the lung’s lining that is almost always caused by previous exposure to asbestos.

It is hoped the new treatment will replace or delay the need for the standard treatment in these cases, a pleural pneumonectomy, which involves removal of the lung and which can be extremely debilitating to patients.

According to a press release from the medical center, Dr. Robert Taub, the study’s principal investigator, director of the Mesothelioma Center at NewYork-Presbyterian/Columbia and professor of clinical medicine at Columbia University College of Physicians and Surgeons, says, “Current surgical and chemotherapy treatments of patients with malignant pleural mesothelioma are unsatisfactory, and have not been shown to significantly prolong survival. In this study, we will investigate whether a combination of chemotherapy and radiation targeted directly at the lung’s lining can improve outcomes while avoiding surgery. In addition, this approach has shown to have minimal toxic side effects compared to systemic chemotherapy.”

The Mesothelioma Center is the only one nationwide that is offering this experimental therapy to treat pleural mesothelioma.

The study is being conducted at the Mesothelioma Center within the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center. According to the release, participating patients will receive several rounds of targeted chemotherapy using the drugs cisplatin and doxorubicin via surgically implanted catheters. Some patients will be randomly selected to receive additional systemic (intravenous) chemotherapy using the drugs cisplatin and pemetrexed. All patients will receive targeted radiotherapy using the P-32 radioisotope.

Patients may elect to receive additional surgical treatment, including removal of the affected lung lining or lung. Subsequently, patients will be offered outpatient systemic chemotherapy with cisplatin and pemetrexed.

For more information, visit www.hiccc.columbia.edu.